<DOC>
	<DOCNO>NCT01295034</DOCNO>
	<brief_summary>The ability vitamin D modulate immune system strengthen bone may mitigate adverse medication consequence HIV/AIDS , little know either health benefit vitamin D supplement , optimal dose regimen patient highly active antiretroviral therapy ( HAART ) . This trial comparison two regimen administer vitamin D calcium HIV-positive individual take antiviral medication . This study help physician make evidence-based decision effective way use vitamin D patient enable design large multi-center trial future .</brief_summary>
	<brief_title>Vitamin D Supplements HIV-positive Patients cART</brief_title>
	<detailed_description>In post-HAART era , patient continue suffer adverse medical consequence HIV/AIDS . The adverse effect include incomplete immune reconstitution , chronic inflammation , depression , increase risk cardiovascular metabolic disease , low bone density . Clinical trial suggest vitamin D supplement increase bone density , reduce inflammation , alleviate depression , increase longevity give adequate dos . To achieve maximum benefit , vitamin D expert HIV field agree vitamin D treatment raise concentration 25-hydroxyvitamin D [ 25 ( OH ) D ] 30 ng/ml . A grow number HIV care provider desire evidence-based protocol achieve 25 ( OH ) D target level . This project address need validate protocol treat vitamin D deficiency HIV-positive individual HAART . The goal Aim I conduct 12-mo randomize , double-blinded trial compare two dose regimen oral vitamin D plus 0.5 g/d calcium patient stable HAART 25 ( OH ) D level â‰¤ 25 ng/ml undetectable HIV viral load baseline ( 100 per arm ) . Medication event monitoring system ( MEMS ) cap use record supplement use promote adherence . Subjects Protocol A receive 50,000 IU/wk vitamin D2 8 wk follow 1000 IU/d vitamin D3 48 wk . Subjects Protocol B receive 2000-4000 IU/d vitamin D3 , depend basal 25 ( OH ) D level , dose titration , necessary , base slope initial response . The primary outcome measure difference percentage subject 25 ( OH ) D level range 30-60 ng/ml 12 mo . The secondary outcome slope 25 ( OH ) D response curve various time interval . The goal Aim II compare impact two protocol marker disease . The primary outcome measure change CD4+T cell count . Secondary outcome include change CD4+ T cell subset , marker inflammation , marker bone calcium metabolism , self-reported psychological status , viral load , side effect , safety , adherence . To knowledge , trial first head-to-head comparison regimen use load dose vitamin D2 regimen us tiered start dose vitamin D3 . The project yield validate protocol treat vitamin D deficiency HIV-infected patient HAART provide initial data risk health benefit vitamin D calcium supplement . This information essential designing definitive multicenter trial future .</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>age , 1870 yr HIVinfected stable HAART regimen least 12 mo undetectable HIV viral load 6mo willing participate receiving vitamin D supplementation form vitamin D2 vitamin D3 receive treatment bone disease receive medication know alter bone mineralization suffer condition know affect vitamin D , calcium , and/or phosphate level ( include clinically significant hypocalcemia , primary hyperparathyroidism ) experience kidney disease base GFR &gt; 60 min/ml/1.73 m2 , 10 ) 25 ( OH ) D level &lt; 25 ng/ml meeting criterion National Osteoporosis Foundation establish bone disease ( osteoporosis , osteomalacia ) require immediate treatment consume 2.0 gm calcium/day food supplement combine outside trial consume 800IU/day vitamin D outside trial suffer unstable medical condition likely preclude participation 12 month trial able ingest absorb food nutrient pregnant plan become pregnant . No history evidence HIV infection HIV viral load positive outside age range</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>combination antiretroviral therapy</keyword>
	<keyword>vitamin D</keyword>
	<keyword>low bone density</keyword>
</DOC>